Milford Hospital

New Milford, CT, United States

Milford Hospital

New Milford, CT, United States

Time filter

Source Type

Burlington, MA, May 04, 2017 (GLOBE NEWSWIRE) -- BURLINGTON, Mass., May 4  2017 – Nuance Communications, Inc. today announced a new wave of hospitals that have selected Nuance computer-assisted physician documentation (CAPD ), powered by artificial intelligence (AI), to combat physician burnout and deliver relevant, clinical guidance at the point of care. With 750 proven clinical strategies and support for coding and regulatory compliance, physicians can improve the quality of documentation in their natural workflow and in the patient’s electronic health record (EHR). Nuance’s market-leading CAPD solutions will be highlighted in Nuance booth #308 at the Association of Clinical Documentation Improvement Specialists (ACDIS) Conference May 9-12 in Las Vegas. “We have seen a significant interest in these intelligent solutions that enhance patient care by providing decision support and clinical documentation improvement (CDI) where and when care happens, not after the fact. This has clinical benefits and has delivered $1 billion a year in appropriate reimbursement back to Nuance hospital clients,” said Satish Maripuri, executive vice president and general manager of the Healthcare Division, Nuance. “Organizations are selecting our CAPD technology to help clinicians improve the quality of clinical documentation immediately and better communicate the patient story to others on the care team.” For example, Carolinas HealthCare, Conway Regional Health, Milford Hospital, Nevada Regional Medical Center, Northeast Georgia Medical Center, St. Bernard Hospital, St. Mark’s Medical Center, Ernest Health and Hannibal Regional Hospital are among the many leading healthcare organizations that have chosen Nuance CAPD solutions to improve the physician and patient experience. These solutions are available stand-alone or embedded directly into the EHR where Nuance technology leverages natural language processing (NLP) and evidence-based guidelines to proactively analyze the entire patient encounter, discover missing information and clarify clinical information to improve the quality of care and the quality of the note. New CAPD Report Nuance’s comprehensive CAPD portfolio and the results achieved by hospitals and health systems throughout the U.S. are described in a new report, “CAPD 2017: Improve physician documentation at the point of care” available here. “As a physician, the real value of the solution is that it’s not disruptive. If you are going to ask a question to clarify something, ask me when I’m in the note, not an hour or a day later. If I’ve moved on, the question is an interruption in my day,” said Ehab Hanna, MD, CMIO, Universal Health Services. Nuance provides intelligent systems that support a more natural and insightful approach to clinical documentation, freeing clinicians to spend more time caring for patients. Nuance healthcare solutions capture, improve and communicate more than 300 million patient stories each year, helping more than 500,000 clinicians in 10,000 global healthcare organizations to drive meaningful clinical and financial outcomes. Nuance’s award-winning clinical speech recognition, medical transcription, CDI, coding, quality and medical imaging solutions provide a more complete and accurate view of patient care. Nuance Communications, Inc. is a leading provider of voice and language solutions for businesses and consumers around the world.  Its technologies, applications and services make the user experience more compelling by transforming the way people interact with devices and systems. Every day, millions of users and thousands of businesses experience Nuance’s proven applications.  For more information, please visit www.nuance.com. Trademark reference: Nuance and the Nuance logo are registered trademarks or trademarks of Nuance Communications, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.


News Article | August 2, 2017
Site: www.prnewswire.com

Under the partnership, Aris will deliver on-site physician coverage and management support to the 106-bed acute care community hospital serving the residents of Greater New Haven and Fairfield Counties. The facility will also have 24/7 access to highly specialized radiologists through Aris' teleradiology network. "As a high performing organization, Milford Hospital recognizes the impact a strong radiology department can have on the quality of its outcomes, the satisfaction of its patients and referring physicians, and the overall efficiency of its operations," said Stephen L Houff, MD, chairman and chief executive officer of Aris Radiology. "We are pleased to partner with Milford Hospital to provide radiology services that support their ongoing quality and performance improvement initiatives." With more than 250 radiologists who interpret an estimated 2.5 million studies annually across 300 client sites, Aris offers 24/7 access to one of the nation's largest networks of subspecialized radiologists. The company also maintains a robust IT platform that helps increase the speed with which both attending physicians and patients receive results. "Radiology and imaging services are a critical aspect in the diagnosis and treatment of our patients. We chose Aris because they share our commitment to meeting – and exceeding – aggressive quality and service standards," said Joseph Pelaccia, president and CEO of Milford Hospital. "Having 24-hour access to highly skilled specialty radiologists on a digital platform helps us provide fast, accurate readings and build stronger relationships with our patients and referring physicians." "Milford Hospital is dedicated to being the health care resource for our community," said Pelaccia. "Partnering with Aris is another way the hospital can ensure our patients are receiving the highest level of care." About Aris Radiology Founded in 2007, Aris Radiology is one of the nation's most established providers of professional radiology services.  As a national radiology group, Aris works with hospitals across the country to help transform imaging departments - creating solutions that elevate performance and deliver lasting results. The group's unique approach enables hospitals to take advantage of its network of board certified, US-based, subspecialty radiologists, as well as a dedicated on-site team of general radiologists, providing expert care regardless of the hospital's size or location. For more information, visit arisradiology.com. About Milford Hospital Milford Hospital is a non-profit community hospital serving more than 60,000 patients from Greater New Haven and Fairfield County annually. Designated a Top Performer in Key Quality Measures by the Joint Commission, a Four Star Health Care Provider by the Centers for Medicare and Medicaid and a Blue Distinction Center + for Quality and Efficiency in Joint Replacement, Milford Hospital is committed to providing safe, compassionate and cost efficient care its patients and the community. For more information, please visit www.milfordhospital.org


Lee S.H.,Milford Hospital | Vigliotti J.S.,Milford Hospital | Vigliotti V.S.,Milford Hospital | Jones W.,Milford Hospital | Shearer D.M.,Therapeutic Research Foundation
International Journal of Molecular Sciences | Year: 2014

The diagnoses of Lyme disease based on clinical manifestations, serological findings and detection of infectious agents often contradict each other. We tested 52 blind-coded serum samples, including 20 pre-treatment and 12 post-treatment sera from clinically suspect Lyme disease patients, for the presence of residual Lyme disease infectious agents, using nested PCR amplification of a signature segment of the borrelial 16S ribosomal RNA gene for detection and direct DNA sequencing of the PCR amplicon for molecular validation. These archived sera were split from the samples drawn for the 2-tier serology tests performed by a CDC-approved laboratory, and are used as reference materials for evaluating new diagnostic reagents. Of the 12 post-treatment serum samples, we found DNA evidence of a novel borrelia of uncertain significance in one, which was also positive for the 2-tier serology test. The rest of the post-treatment sera and all 20 control sera were PCR-negative. Of the 20 pre-treatment sera from clinically suspect early Lyme disease patients, we found Borrelia miyamotoi in one which was 2-tier serology-negative, and a Borrelia burgdorferi in two-one negative and one positive for 2-tier serology. We conclude that a sensitive and reliable DNA-based test is needed to support the diagnosis of Lyme disease and Lyme disease-like borreliosis. © 2014 by the authors; licensee MDPI, Basel, Switzerland.


Silverman R.A.,Long Island Jewish Medical Center | Silverman R.A.,Feinstein Institute for Medical Research | Foley F.,Long Island Jewish Medical Center | Dalipi R.,Long Island Jewish Medical Center | And 4 more authors.
Respiratory Medicine | Year: 2012

Introduction: Mucous plugging is associated with fatal asthma and may have a causative role for non-fatal cases of severe acute asthma. However, mucolytic agents have not been found effective in reversing the obstruction of acute asthma. We test the hypothesis that rhDNAse, an agent that reduces viscoelasticity of sputum in patients with cystic fibrosis, has a therapeutic role in acute asthma. Methods: Symptomatic asthmatics aged 18-55 years presenting to an Emergency Department with an FEV 1 < 60% predicted after 2 nebulized albuterol and ipratropium treatments were included. Patients were randomized into one of three nebulized rhDNAse treatment groups of2.5, 5.0 or 7.5 mg, or placebo. Standardized bronchodilator therapy was continued throughout the protocol and the FEV 1 at 6 h was the primary study endpoint. Results: 50 patients were enrolled. There were no significant differences in FEV 1% predicted between the rhDNAse and placebo patients at any of the post-randomization time points. The dose of rhDNAse administered did not influence response. In a post-hoc stratification, patients with the lowest pre-randomization FEV 1 tended to improve more from rhDNAse, particularly at times 60 and 120 min post-randomization. Conclusion: In this pilot study rhDNAse did not cause clinical improvement among severely ill adults refractory to standardized care. The observed trend to higher FEV 1 among the most severely obstructed patients is an exploratory finding that may warrant further study. This clinical trial was registered as NCT00169962 under the name "Study of Pulmozyme to Treat Severe Asthma Episodes". © 2012 Elsevier Ltd. All rights reserved.


Lee S.H.,Milford Hospital
Current Medicinal Chemistry | Year: 2014

Gardasil® is a quadrivalent human papillomavirus (HPV) protein-based vaccine containing genotype-specific L1 capsid proteins of HPV-16, HPV-18, HPV-6 and HPV-11 in the form of virus-like-particles (VLPs) as the active ingredient. The VLPs are produced by a DNA recombinant technology. It is uncertain if the residual HPV L1 gene DNA fragments in the vaccine products are considered contaminants or excipients of the Gardasil® vaccine. Because naked viral DNA fragments, if present in the vaccine, may bind to the insoluble amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant which may help deliver the foreign DNA into macrophages, causing unintended pathophysiologic effects, experiments were undertaken to develop tests for HPV L1 gene DNA fragments in the final products of Gardasil® by polymerase chain reaction (PCR) and direct DNA sequencing. The results showed that while the HPV-11 and HPV-18 L1 gene DNA fragments in Gardasil® were readily amplified by the common GP6/MY11 degenerate consensus primers, the HPV-16 L1 gene DNA may need specially designed non-degenerate PCR primers for amplification at different regions of the L1 gene and different stringency conditions for detection. These variable melting profiles of HPV DNA in the insoluble fraction of the Gardasil® vaccine suggest that the HPV DNA fragments are firmly bound to the aluminum AAHS adjuvant. All methods developed for detecting residual HPV DNA in the vaccine Gardasil® for quality assurance must take into consideration the variable melting profiles of the DNA to avoid false negative results. © 2014 Bentham Science Publishers.


Medical practitioners in nine countries submitted samples of Gardasil® (Merck & Co.) to be tested for the presence of human papillomavirus (HPV) DNA because they suspected that residual recombinant HPV DNA left in the vaccine might have been a contributing factor leading to some of the unexplained post-vaccination side effects. A total of 16 packages of Gardasil® were received from Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain and the United States. A nested polymerase chain reaction (PCR) method using the MY09/MY11 degenerate primers for initial amplification and the GP5/GP6-based nested PCR primers for the second amplification were used to prepare the template for direct automated cycle DNA sequencing of a hypervariable segment of the HPV L1 gene which is used for manufacturing of the HPV L1 capsid protein by a DNA recombinant technology in vaccine production. Detection of HPV DNA and HPV genotyping of all positive samples were finally validated by BLAST (Basic Local Alignment Search Tool) analysis of a 45-60 bases sequence of the computer-generated electropherogram. The results showed that all 16 Gardasil® samples, each with a different lot number, contained fragments of HPV-11 DNA, or HPV-18 DNA, or a DNA fragment mixture from both genotypes. The detected HPV DNA was found to be firmly bound to the insoluble, proteinase-resistant fraction, presumably of amorphous aluminum hydroxyphosphate sulfate (AAHS) nanoparticles used as adjuvant. The clinical significance of these residual HPV DNA fragments bound to a particulate mineral-based adjuvant is uncertain after intramuscular injection, and requires further investigation for vaccination safety. © 2012 Elsevier Inc. All rights reserved.


Accurate genotyping of a human papilloma virus (HPV) isolated from clinical specimens depends on molecular identification of the unique and exclusive nucleotide base sequence in the hypervariable region of a highly conserved segment of the HPV L1 gene. Among other options, a heminested (nested) polymerase chain reaction (PCR) technology using two consecutive PCR replications of the target DNA in tandem with three consensus general primers may be used to detect a minute quantity of HPV DNA in crude proteinase K digestate of cervicovaginal cells, and to prepare the template for genotyping by automated direct DNA sequencing. A short target sequence of 40-60 bases excised from the computer-generated electropherogram is sufficient for BLAST determination of all clinically relevant HPV genotypes, based on the database stored in the GenBank. This chapter discusses the principle and the essential technical elements in performing nested PCR DNA amplification for the detection of HPV from clinical specimens and short target sequence genotyping for HPV, using standard molecular biology laboratory equipment and commercially available reagents. © 2012 Springer Science+Business Media New York.


Lee S.H.,Milford Hospital | Vigliotti V.S.,Milford Hospital | Pappu S.,Milford Hospital
Journal of Clinical Pathology | Year: 2010

Aims: Persistent infection indicated by detection of human papillomavirus 16 (HPV-16) on repeat testing over a period of time poses the greatest cervical cancer risk. However, variants of HPV-16, HPV-31 and HPV-33 may share several short sequence homologies in the hypervariable L1 gene commonly targeted for HPV genotyping. The purpose of this study was to introduce a robust laboratory procedure to validate HPV-16 detected in clinical specimens, using the GenBank sequence database as the standard reference for genotyping. Methods: A nested PCR with two pairs of consensus primers was used to amplify the HPV DNA released in crude proteinase K digest of the cervicovaginal cells in liquid-based Papanicolaou cytology specimens. The positive nested PCR products were used for direct automated DNA sequencing. Results: A 48-base sequence downstream of the GP5+ priming site, or a 34-base sequence upstream thereof, was needed for unequivocal validation of an HPV-16 isolate. Selection of a 45-base, or shorter, sequence immediately downstream of the GP5+ site for Basic Local Alignment Search Tool sequence analysis invariably led to ambiguous genotyping results. Conclusions: DNA sequence analysis may be used for differential genotyping of HPV-16, HPV-31 and HPV-33 in clinical specimens. However, selection of the signature sequence for Basic Local Alignment Search Tool algorithms is crucial to distinguish certain HPV-16 variants from other closely related HPV genotypes.


Lee S.H.,Milford Hospital | Vigliotti V.S.,Milford Hospital | Vigliotti J.S.,Milford Hospital | Jones W.,Milford Hospital | Pappu S.,Milford Hospital
American Journal of Clinical Pathology | Year: 2010

The DNA of Borrelia burgdorferi spirochetes extracted by ammonium hydroxide was used as the template for nested polymerase chain reaction (PCR) amplification of the species-specific 16S ribosomal DNA (rDNA). The primers were those well known to be specific for signature sequence amplification of the B burgdorferi sensu lato 16S ribosomal RNA gene. The positive 293-base-pair nested PCR amplicon was subjected to routine direct automated Sanger sequencing. A 50-base sequence excised randomly from the sequencing electrophoretogram between the 2 nested PCR primer binding sites was sufficient for the Basic Local Alignment Search Tool (BLAST) analysis to validate the B burgdorferi sensu lato 16S rDNA without a reasonable doubt. Nested PCR increased the sensitivity of DNA detection by 100- to 1,000-fold. DNA sequence validation based on BLAST algorithms using the GenBank database practically eliminates any possibility of false-positive results due to molecular misidentification. This technology may be a valuable supplement to the current serologic tests for Lyme disease. © American Society for Clinical Pathology.


Lee S.H.,Milford Hospital | Vigliotti J.S.,Milford Hospital | Vigliotti V.S.,Milford Hospital | Jones W.,Milford Hospital
Cancers | Year: 2014

The newly gained knowledge of the viral etiology in cervical carcinogenesis has prompted industrial interests in developing virology-based tools for cervical cancer prevention. Due to the long incubation period from viral infection to developing an invasive cancer, a process whose outcome is influenced by numerous life-style and genetic factors, the true efficacy of the genotype-specific human papillomavirus (HPV) vaccines in cervical cancer prevention cannot be determined for another 30 years. Most HPV DNA test kits designed to replace the traditional Papanicolaou (Pap) smears for precancer detection lack the analytical sensitivity and specificity to comprehensively detect all potentially carcinogenic HPVs and to perform reliable genotyping. The authors implemented the classic nested PCR and Sanger DNA-sequencing technology for routine HPV testing. The results showed a true negative HPV PCR invariably indicates the absence of precancerous cells in the cytology samples. However, 80.5% of single positive HPV-16 tests and 97.3% of single positive HPV-18 tests were associated with a negative or a largely self-reversible Pap cytology. Routine sensitive and reliable HPV type-specific or perhaps even variant-specific methods are needed to address the issues of persistence of HPV infection if a virology-based primary cervical screen is used to replace the Pap cytology screening paradigm. © 2014 by the authors; licensee MDPI, Basel, Switzerland.

Loading Milford Hospital collaborators
Loading Milford Hospital collaborators